The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.

Patients will receive three weeks of whole brain radiation therapy concurrent with daily motexafin gadolinium during weeks 2 and 3, followed by a stereotactic radiosurgery boost concurrent with motexafin gadolinium. Patients will be followed for radiologic response, neurologic progression, and neurocognitive progression.

Inclusion Criteria:

• Age ≥ 18 years
• Karnofsky performance status (KPS) ≥ 70
• Histologically confirmed malignancy with the presence of one to four intraparenchymal brain metastases
• Each patient must sign a study-specific Informed Consent form

Exclusion Criteria:

• Previous cranial radiation
• Complete resection of all known brain metastases
• Known leptomeningeal metastases
• Known liver metastases
• Clinical or radiologic evidence of progression (other than study lesion[s) within 1 month prior to enrollment
• Patients with metastases within 10 mm of the optic apparatus
• Patients with metastases in the brainstem, midbrain, pons, or medulla
• Planned chemotherapy during WBRT and/or SRS
• Uncontrolled hypertension
• Women who are pregnant or lactating

and Laboratory values as follows:

• LDH > 1.3 x upper limit of normal (ULN)
• ANC < 1500/mm3
• Platelets < 50,000/mm3
• Creatinine > 2.0 mg/dL
• AST or ALT > 3 x ULN
• Total bilirubin > 2 x ULN](streamdown:incomplete-link)